MX2021014116A - Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3). - Google Patents

Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).

Info

Publication number
MX2021014116A
MX2021014116A MX2021014116A MX2021014116A MX2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A
Authority
MX
Mexico
Prior art keywords
compounds
inhibitors
relates
pyridopyrimidines
derivatives
Prior art date
Application number
MX2021014116A
Other languages
English (en)
Inventor
Matteo Biagetti
Roberta Lanaro
Claudio Fiorelli
Paolo Bruno
Charles Baker-Glenn
De Poël Hervè Van
Stephen David Penrose
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2021014116A publication Critical patent/MX2021014116A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula I que inhiben el purinoreceptor 3 de P2X (en lo sucesivo inhibidores de P2X3); la invención se refiere particularmente a compuestos que son derivados de piridopirimidinas, métodos para preparar estos compuestos, composiciones farmacéuticas que los contienen y uso terapéutico de los mismos. Los compuestos de la invención pueden ser útiles en el tratamiento de muchos trastornos asociados con mecanismos de los receptores P2X3, tales como enfermedades respiratorias que incluyen tos, asma, fibrosis pulmonar idiopática (IPF) y enfermedad pulmonar obstructiva crónica (COPD).
MX2021014116A 2019-05-31 2020-05-28 Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3). MX2021014116A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19177610 2019-05-31
EP19201165 2019-10-02
PCT/EP2020/064915 WO2020239953A1 (en) 2019-05-31 2020-05-28 Pyridopyrimidines derivatives as p2x3 inhibitors

Publications (1)

Publication Number Publication Date
MX2021014116A true MX2021014116A (es) 2021-12-10

Family

ID=70857198

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014116A MX2021014116A (es) 2019-05-31 2020-05-28 Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).

Country Status (11)

Country Link
US (1) US20230212169A9 (es)
EP (1) EP3976609A1 (es)
JP (1) JP2022534434A (es)
KR (1) KR20220016074A (es)
CN (1) CN114222741A (es)
AU (1) AU2020281924A1 (es)
BR (1) BR112021020279A2 (es)
CA (1) CA3136024A1 (es)
MA (1) MA56020A (es)
MX (1) MX2021014116A (es)
WO (1) WO2020239953A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022160931A1 (zh) * 2021-01-28 2022-08-04 浙江海正药业股份有限公司 吡啶并嘧啶类衍生物及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4342007B2 (ja) * 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
EP1924264B9 (en) * 2005-09-01 2014-02-19 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
CN103159692B (zh) 2006-06-29 2015-03-18 弗·哈夫曼-拉罗切有限公司 四唑取代的芳基酰胺类
JP5396379B2 (ja) * 2007-04-02 2014-01-22 エボテック・アーゲー ピリド−２−イル縮合複素環式化合物ならびにその組成物および使用
US8076345B2 (en) 2007-04-17 2011-12-13 Evotec Ag 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof
WO2009110985A2 (en) 2008-02-29 2009-09-11 Renovis, Inc. Amide compounds, compositions and uses thereof
CA2737038A1 (en) 2008-09-18 2010-03-25 Evotec Ag Amide compounds, compositions and uses thereof
WO2011041655A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Quinazolin-4-amine derivatives; and methods of use
WO2012064973A2 (en) * 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016084922A1 (ja) 2014-11-28 2016-06-02 塩野義製薬株式会社 １，２，４－トリアジン誘導体およびその医薬組成物
JPWO2016088838A1 (ja) 2014-12-04 2017-09-14 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
KR20230098368A (ko) 2014-12-09 2023-07-03 바이엘 악티엔게젤샤프트 1,3-티아졸-2-일 치환된 벤즈아미드
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
US11260056B2 (en) 2015-09-29 2022-03-01 Afferent Pharmaceuticals, Inc. Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough
WO2017091661A1 (en) * 2015-11-25 2017-06-01 Strovel Jeffrey William Bicyclic bet bromodomain inhibitors and uses thereof
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
CA3107556C (en) * 2018-07-25 2022-10-25 Faes Farma, S.A. Pyridopyrimidines as histamine h4-receptor inhibitors

Also Published As

Publication number Publication date
BR112021020279A2 (pt) 2021-12-14
JP2022534434A (ja) 2022-07-29
KR20220016074A (ko) 2022-02-08
EP3976609A1 (en) 2022-04-06
WO2020239953A1 (en) 2020-12-03
CA3136024A1 (en) 2020-12-03
MA56020A (fr) 2022-04-06
US20220235060A1 (en) 2022-07-28
CN114222741A (zh) 2022-03-22
AU2020281924A1 (en) 2021-12-16
US20230212169A9 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
MX2021014113A (es) Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3).
SA519402319B1 (ar) Rho- مشتقات أميد التيروسين كمثبطات لإنزيم الكيناز
MX2019005526A (es) Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa.
PH12016501439B1 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
JOP20200286A1 (ar) بنزاميدات مستبدلة بـ 1 ، 3-ثيازول-2-يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية
MX2021000270A (es) Derivados de la tirosina amida como inhibidores de la rho- cinasa.
MX371178B (es) Orvepitant para el tratamiento de la tos crónica.
WO2016168553A8 (en) Deuterated obeticholic acid
MX2022013014A (es) Nuevas formas cristalinas de trifenatato de vilanterol y procedimientos para su preparacion.
JOP20200314A1 (ar) تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
MX2021014116A (es) Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).
MX2023005805A (es) Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3).
MX2023005801A (es) Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3).
MX2016001539A (es) Particulas inhalables que comprenden tiotropio e indacaterol.
MX2023005803A (es) Derivados de amino-quinazolina como inhibidores del purinorreceptor 3 p2x (p2x3).
MX2021015553A (es) Inhibidores de arginasa novedosos.
EA202193300A1 (ru) Производные аминохиназолина в качестве p2x3 ингибиторов
MX2023005867A (es) Derivados de dihidrofuropiridina como inhibidores de la cinasa rho.
MX2023005865A (es) Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.
MX2023005866A (es) Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.
PH12017500378A1 (en) Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid
MX2022004809A (es) Composiciones para prevenir o tratar enfermedad pulmonar obstructiva cronica (epoc).
NZ761390A (en) Boysenberry, apple, and blackcurrant compositions and methods of preparation and use therefor
TR201720845A1 (tr) Oral farmasöti̇k terki̇pler
TR201716209A2 (tr) Arformoterol ve umeklidinyum içeren yeni farmasötik bileşimler.